RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials

RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials. The goal of these services is to stretch project funds further, ensuring greater impact and cost savings. Below is the list of subsidized services offered:

 

100% Subsidized Services (RareKids-CAN will cover 100% of the cost of the following services):

    • Consultations: We will conduct a robust consultation to identify areas of needs for your project with valuable involvement from relevant sub platforms based on your project needs to ensure your project receives adequate support.
    • High-level project management: An experienced project manager will ensure efficient coordination, oversight, and successful execution from inception to completion for your clinical trial.
    • Database build (not including management): We will provide project-specific electronic case report form (e-CRF) development and database management in a validated REDCap database housed at the Women and Children’s Health Research Institute (WCHRI).
    • Data Safety Monitoring Board: From our repository of individuals with specific expertise relevant to your project, we facilitate a centralized data safety monitoring board to ensure participant safety and provide expertise on clinical trial conduct for continuation, modification, or termination.

 

50% Subsidized Services (RareKids-CAN will cover 50% of the total cost of the following services):

    • Regulatory submissions: We assist study teams in the preparation and submission of clinical trial applications, investigational testing authorizations, and single-patient study applications for regulated clinical trials to Health Canada. We will also assist in adverse event reporting.
    • Monitoring: We have a dedicated and experienced monitoring team to perform risk-based remote and on-site monitoring to meet the Health Canada required sponsor obligations.

All other services are 100% cost recovered (i.e., RareKids-CAN will not subsidize)

 

If you have a clinical trial that require these services or would like to further discuss, you can complete the project intake form.

RareKids-CAN logo

Read next...

Text reading NMD4C joins bluesky - We're now active on Bluesky! We invite you to follow us at @nmd4c.ca to stay updated on news from our Canadian neuromuscular network. NMD4C and bluesky logo, with an image of the NMD4C bluesky feed.

You Can Now Find NMD4C on Bluesky

We’re moving to Bluesky! The NMD4C will now share updates on Bluesky instead of X. Please consider following us at @nmd4c.ca to stay connected! 

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces The NMD4C is excited to share that network investigators Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota and Malcolm King have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces

The NMD4C is excited to share that network investigators have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies.

2025 NMD4C early career award winners profile pictures, text reading Congratulations Early Career Award Winners

NMD4C Presents the 2025 Early Career Award Recipients

We are excited to announce the recipients of the 2025 NMD4C Early Career Awards! This is the third year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

LEARNMD content update - February 2025

New Content Available in LEARNMD

LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!

RQAS logo

Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group

We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C